“The world’s first personalised mRNA cancer vaccine for melanoma halves the risk of patients dying or the disease returning, according to trial results that doctors described as ‘extremely impressive.’

Melanoma affects more than 150,000 people a year globally, according to 2020 figures from World Cancer Research Fund International.

Patients who received the vaccine after having a stage 3 or 4 melanoma removed had a 49% lower risk of dying or the disease recurring after three years, data presented at the world’s largest cancer conference showed.”

From The Guardian.